Abstract:Research ethics: Our study was performed according to the Helsinki Declaration, with full respect for individuals' right to confidentiality. Informed consent: Our study was performed with a waiver of informed consent, approved by the AZ Delta Ethical Committee (Clinical Trial No. IRB B1172020000008). Author contributions: The authors have accepted responsibility for the entire content of this manuscript and approved its submission. Conceptualization: PH, HV, DD. Methodology: PH, HV, DD. Validation: PH, HV, DD. Formal analysis: PH. Investigation: PH, HV, DD. Writing – original draft: PH. Writing – review and editing: HV, DD, FB, AD, ID, JD, GM. Supervision: HV, DD. Competing interests: The authors state no conflict of interest. Research funding: None declared. Data availability: The raw data can be obtained on request from the corresponding author. 1. Iijima, H, Kobayashi, T, Nagasaka, M, Shinzaki, S, Kitamura, K, Kitamura, K, et al.. Management of primary nonresponders and partial responders to tumor necrosis factor-α inhibitor induction therapy among patients with Crohn's disease. Inflamm Intest Dis 2020;5:78–83. https://doi.org/10.1159/000506337. Search in Google Scholar PubMed PubMed Central 2. Gorovits, B, Baltrukonis, DJ, Bhattacharya, I, Birchler, MA, Finco, D, Sikkema, D, et al.. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab. Clin Exp Immunol 2018;192:348–65. https://doi.org/10.1111/cei.13112. Search in Google Scholar PubMed PubMed Central 3. Pouw, M, Krieckaert, C, Nurmohamed, M, van der Kleij, D, Aarden, L, Rispens, T, et al.. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis 2013;74:513–8. https://doi.org/10.1136/annrheumdis-2013-204172. Search in Google Scholar PubMed 4. Vande Casteele, N, Ferrante, M, Van Assche, G, Ballet, V, Compernolle, G, Van Steen, K, et al.. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015;148:1320–9. https://doi.org/10.1053/j.gastro.2015.02.031. Search in Google Scholar PubMed 5. Schmitz, E, Van De Kerkhof, D, Hamann, D, Van Dongen, J, Kuijper, P, Brunsveld, L, et al.. Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits. Clin Chem Lab Med 2016;54:1211–9. https://doi.org/10.1515/cclm-2015-0987. Search in Google Scholar PubMed 6. Van Den Bossche, D, De Smet, D, Debrabandere, J, Vanpoucke, H. Analytical and clinical performance evaluation of two POC tests for therapeutic drug monitoring of infliximab. Clin Chem Lab Med 2019;57:856–63. https://doi.org/10.1515/cclm-2018-0891. Search in Google Scholar PubMed 7. Berger, A, Gleizes, A, Waeckel, L, Roblin, X, Krzysiek, R, Hacein-Bey-Abina, S, et al.. Validation study of a new random-access chemiluminescence immunoassay analyzer i-TRACK10 to monitor infliximab and adalimumab serum trough levels and anti-drug antibodies. Int J Mol Sci 2022;23:9561. https://doi.org/10.3390/ijms23179561. Search in Google Scholar PubMed PubMed Central 8. Rissel, F, Cazaubon, Y, Saffar, S, Altwegg, R, Artasone, M, Lozano, C, et al.. Comparative evaluation of four commercially available immunoassays for therapeutic drug monitoring of infliximab and adalimumab. Int J Mol Sci 2023;24:10379. https://doi.org/10.3390/ijms241210379. Search in Google Scholar PubMed PubMed Central 9. EMEA . Guideline on bioanalytical method validation . London, UK: European Medicines Agency; 2011. Search in Google Scholar © 2024 Walter de Gruyter GmbH, -Abstract Truncated-

Early monitoring of anti-infliximab antibodies by drug-tolerant assay predicts later immunogenicity and drug survival in rheumatic diseases

P251 Proactive Therapeutic drug monitoring of Infliximab, but not HLA-DQA1*05, predicts clinical outcome in inflammatory bowel disease

P337 Proactive therapeutic drug monitoring of Adalimumab, but not HLADQ*A1 determination, predicts inflammatory bowel disease outcome and persistence of treatment

The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study

P583 Infliximab Monitoring in Crohn's Disease and Development of Neural Networks Using Clinical Variables to Predict Disease Activity and Immunogenicity

Therapeutic Drug Monitoring of Infliximab and Adalimumab through Concentration and Anti-Drug Antibodies Assessment; Comparison of Sanquin Diagnostics and Theradiag Assays

Long‐term follow‐up of anti‐infliximab antibodies in radiographic axial spondyloarthritis patients: a marker of drug survival and tapering

Dynamics and implications of anti-drug antibodies against adalimumab using ultra-sensitive and highly drug-tolerant assays

Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials

Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays

Association of short-term efficacy for infliximab in rheumatoid arthritis with plasma concentration and anti-drug antibody

P1021 Comparison of subcutaneous and intravenous infliximab in patients with inflammatory bowel disease showed no differences in immunogenicity or treatment persistence at one year

P874 Impact of immunogenicity on clinical outcomes in patients with Crohn’s disease receiving maintenance treatment with subcutaneous infliximab: A post hoc analysis of the LIBERTY-CD study

P851 Therapeutic drug monitoring of infliximab and adalimumab versus clinical control during maintenance therapy in patients with Inflammatory Bowel Disease

P668 Dashboard-guided anti-TNF induction as an effective proactive strategy in Inflammatory Bowel Disease's treatment

Analytical and diagnostic performance of Theradiag i-Tracker assays on IDS-iSYS for infliximab and adalimumab therapeutic drug monitoring

Patients with multiple sclerosis who develop immunogenicity to interferon-beta have distinct transcriptomic and proteomic signatures prior to treatment which are associated with disease severity

Fluorescence-Based Lateral Flow Immunoassay for Quantification of Infliximab: Analytical and Clinical Performance Evaluation

P468 Relevance of anti-drug antibodies in context of supra-therapeutic anti-TNF concentrations

P058 The identification of three linear epitopes on infliximab all map to complementarity-determining regions

Evaluation of the Homogenous Mobility Shift Assay for Infliximab and Adalimumab Anti-drug Antibody Detection in the Clinical Laboratory